Patents by Inventor Bruce Fahr

Bruce Fahr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING
    Publication number: 20240374579
    Abstract: Disclosed herein are 15-hydroxyprostaglandin dehydrogenase inhibitor compounds. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.
    Type: Application
    Filed: July 27, 2022
    Publication date: November 14, 2024
    Inventors: Sundeep DUGAR, Bruce FAHR, Roopa RAI, Michael J. GREEN
  • PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING
    Publication number: 20240294519
    Abstract: Disclosed herein are 15-hydroxyprostaglandin dehydrogenase inhibitor compounds, including variations of pyrrolopy-rimidines. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.
    Type: Application
    Filed: July 27, 2022
    Publication date: September 5, 2024
    Inventors: Sundeep DUGAR, Bruce FAHR, Roopa RAI, Michael J. GREEN
  • Methods and compounds for restoring mutant p53 function
    Patent number: 11926632
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 12, 2024
    Assignee: PMV Pharmaceuticals, Inc.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20240043436
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 7, 2023
    Publication date: February 8, 2024
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
  • Methods and compounds for restoring mutant p53 function
    Patent number: 11814373
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 14, 2023
    Assignee: PMV PHARMACEUTICALS, INC.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
  • Methods and compounds for restoring mutant p53 function
    Patent number: 11807644
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: November 7, 2023
    Assignee: PMV PHARMACEUTICALS, INC.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20230312539
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 2, 2023
    Publication date: October 5, 2023
    Inventors: Binh VU, Romyr DOMINIQUE, Hongju LI, Bruce FAHR, Andrew GOOD
  • Methods and compounds for restoring mutant p53 function
    Patent number: 11731953
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: August 22, 2023
    Assignee: PMV PHARMACEUTICALS, INC.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20230056253
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 22, 2021
    Publication date: February 23, 2023
    Inventors: Binh VU, Romyr DOMINIQUE, Hongju LI, Bruce FAHR, Yi CHEN
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20230046427
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 16, 2023
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20230002403
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: May 11, 2021
    Publication date: January 5, 2023
    Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
  • METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
    Publication number: 20220315564
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: September 22, 2020
    Publication date: October 6, 2022
    Inventors: Binh VU, Romyr DOMINIQUE, Hongju LI, Bruce FAHR, Andrew GOOD
  • AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20130005707
    Abstract: Provided herein are Heteroaryl Compounds of formula (I): wherein R1 and R2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Inventors: Sogole Bahmanyar, R.J. Bates, Kate Blease, Andrew Antony Calabrese, Thomas Oran Daniel, Mercedes Delgado, Jan Elsner, Paul Erdman, Bruce Fahr, Gregory Ferguson, Branden Lee, Lisa Nadolny, Garrick Packard, Patrick Papa, Veronique Plantevin-Krenitsky, Jennifer Riggs, Patricia Rohane, Sabita Sankar, John Sapienza, Yoshitaka Satoh, Victor Sloan, Randall Stevens, Lida Tehrani, Jayashree Tikhe, Eduardo Torres, Andrew Wallace, Brandon Wade Whitefield, Jingjing Zhao
  • Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
    Patent number: 8299056
    Abstract: Provided herein are Heteroaryl Compounds of formula (I): wherein R1 and R2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: October 30, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sogole Bahmanyar, R.J. Bates, Kate Blease, Andrew Calabrese, Thomas Daniel, Mercedes Delgado, Jan Elsner, Paul Erdman, Bruce Fahr, Gregory Ferguson, Branden Lee, Lisa Nadolny, Garrick Packard, Patrick Papa, Veronique Plantevin-Krenitsky, Jennifer Riggs, Patricia Rohane, Sabita Sankar, John Sapienza, Yoshitaka Satoh, Victor Sloan, Randall Stevens, Lida Tehrani, Jayashree Tikhe, Eduardo Torres, Andrew Wallace, Brandon Wade Whitefield, Jingjing Zhao
  • Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 8211904
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: July 3, 2012
    Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.
    Inventors: Craig A. Coburn, Melissa S. Egbertson, Samuel L. Graham, Georgia B. McGaughey, Shaun R. Stauffer, Hemaka A. Rajapakse, Philippe G. Nantermet, Shawn J. Stachel, Wenjin Yang, Wanli Lu, Bruce Fahr
  • Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 8114887
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: February 14, 2012
    Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.
    Inventors: James C. Barrow, Craig A. Coburn, Melissa S. Egbertson, Georgia B. McGaughey, Melody A. McWherter, Lou Anne Neilson, Kenneth E. Rittle, Harold G. Selnick, Shaun R. Stauffer, Zhi-Qiang Yang, Wenjin Yang, Wanli Lu, Bruce Fahr
  • Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
    Publication number: 20100298342
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: September 4, 2007
    Publication date: November 25, 2010
    Applicants: MERCK & CO., INC., SUNESIS PHARMACEUTICALS, INC.
    Inventors: Melissa S. Egbertson, Shaun R. Stauffer, Craig A. Coburn, James C. Barrow, Lou Anne Neilson, Jenny M. Wai, Wenjin Yang, Wanli Lu, Bruce Fahr
  • AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20100093698
    Abstract: Provided herein are Heteroaryl Compounds of formula (I): wherein R1 and R2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.
    Type: Application
    Filed: September 8, 2009
    Publication date: April 15, 2010
    Inventors: Sogole Bahmanyar, R.J. Bates, Kate Blease, Andrew Antony Calabrese, Thomas Oran Daniel, Mercedes Delgado, Jan Elsner, Paul Erdman, Bruce Fahr, Gregory Ferguson, Branden Lee, Lisa Nadolny, Garrick Packard, Patrick Papa, Veronique Plantevin-Krenitsky, Jennifer Riggs, Patricia Rohane, Sabita Sankar, John Sapienza, Yoshitaka Satoh, Victor Sloan, Randall Stevens, Lida Tehrani, Jayashree Tikhe, Eduardo Torres, Andrew Wallace, Brandon Wade Whitefield, Jingjing Zhao
  • Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease
    Publication number: 20070197571
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: October 12, 2005
    Publication date: August 23, 2007
    Inventors: James Barrow, Craig Coburn, Melissa Egbertson, Georgia McGaughey, Melody McWherter, Lou Neilson, Kenneth Rittle, Harold Selnick, Shaun Stauffer, Zhi-Qiang Yang, Wenjin Yang, Wanli Lu, Bruce Fahr
  • Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
    Publication number: 20070021454
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: July 14, 2006
    Publication date: January 25, 2007
    Inventors: Craig Coburn, Melissa Egbertson, Samuel Graham, Georgia McGaughey, Shaun Stauffer, Hemaka Rajapakse, Philippe Nantermet, Shawn Stachel, Wenjin Yang, Wanli Lu, Bruce Fahr